黃 瑋 高 立 張永利
宮頸癌根治術(shù)腹腔鏡與開腹手術(shù)的臨床對(duì)照研究
黃 瑋 高 立 張永利
目的對(duì)比宮頸癌根治術(shù)腹腔鏡與開腹手術(shù)的療效及安全性。方法選取60例宮頸癌患者,隨機(jī)分為2組。對(duì)照組(30例)采用開腹手術(shù)進(jìn)行治療,觀察組(30例)采用腹腔鏡下宮頸癌根治術(shù)。觀察并記錄2組圍手術(shù)期指標(biāo),切除范圍,術(shù)后24 h、1個(gè)月、3個(gè)月的VAS評(píng)分及隨訪3個(gè)月期間并發(fā)癥發(fā)生情況,評(píng)價(jià)2種手術(shù)方法的療效及安全性。結(jié)果觀察組患者手術(shù)時(shí)間長(zhǎng)于對(duì)照組患者,但術(shù)中出血量少于對(duì)照組(P<0.05),排氣時(shí)間也短于對(duì)照組(P<0.05);2組淋巴結(jié)清掃數(shù)目、術(shù)后留置尿管時(shí)間相比,無(wú)統(tǒng)計(jì)學(xué)差異(P>0.05);2組切除范圍相比,無(wú)統(tǒng)計(jì)學(xué)差異(P>0.05)。術(shù)后24 h內(nèi),2組VAS評(píng)分相比,無(wú)統(tǒng)計(jì)學(xué)差異(P>0.05);術(shù)后1個(gè)月、3個(gè)月,觀察組VAS評(píng)分低于對(duì)照組(P<0.05)。隨訪3個(gè)月期間,觀察組總并發(fā)癥發(fā)生率26.7%,顯著低于對(duì)照組的53.3%(P<0.05)。結(jié)論腹腔鏡下宮頸癌根治術(shù)對(duì)宮頸癌具有較好的治療效果,手術(shù)創(chuàng)傷小,對(duì)內(nèi)臟器官干擾小,術(shù)后疼痛感輕,并發(fā)癥少,值得臨床推廣。
開腹手術(shù);腹腔鏡手術(shù);宮頸癌根治術(shù);宮頸癌;并發(fā)癥
宮頸癌是位居全球婦女惡性腫瘤發(fā)病率第2位的惡性腫瘤,具有較高的致死率,宜早期診斷、早期治療。中晚期宮頸癌患者5年生存率較低,放化療治療效果較差,容易發(fā)生復(fù)發(fā)和轉(zhuǎn)移,因此臨床治療仍以手術(shù)切除為主[1]。為了提高患者生活質(zhì)量,減少術(shù)后并發(fā)癥,多采用以腹腔鏡為代表的微創(chuàng)手術(shù)進(jìn)行治療,腹腔鏡手術(shù)具有創(chuàng)傷小、切口小,患者恢復(fù)快等優(yōu)點(diǎn),被廣泛應(yīng)用于宮頸癌各階段的手術(shù)治療,療效和安全性得到肯定[2]。
選取60例在我院進(jìn)行治療的宮頸癌患者,年限:2014年2月至2016年2月。納入標(biāo)準(zhǔn):①術(shù)前經(jīng)陰道鏡下宮頸活檢確診為宮頸癌;②所有病例按國(guó)際婦產(chǎn)科聯(lián)盟(FIGO2000)分期標(biāo)準(zhǔn)進(jìn)行分期[3];③術(shù)前病理類型均為宮頸鱗狀細(xì)胞癌;④經(jīng)本院倫理委員會(huì)同意,術(shù)前患者均簽署書面知情同意書。排除標(biāo)準(zhǔn):合并肝腎功能異常、泌尿系統(tǒng)疾病、慢性結(jié)腸炎、嚴(yán)重精神疾病的患者。按隨機(jī)數(shù)字表法將患者分為2組,對(duì)照組(30例)患者行開腹手術(shù),觀察組(30例)患者行腹腔鏡下宮頸癌根治術(shù)。對(duì)照組平均年齡(44.7±8.8)歲,臨床分期Ⅰa期 8例、Ⅰb1期 10例、Ⅰb2期 5例、Ⅱa期 7例。觀察組平均年齡(45.9±9.7)歲,臨床分期Ⅰa期 7例、Ⅰb1期 9例、Ⅰb2期 5例、Ⅱa期 9例。2組患者病例資料具有可比性。
觀察組:術(shù)前做好腸道準(zhǔn)備,采用氣管插管麻醉。麻醉成功后患者取膀胱截石位、頭低足高,氣腹針由臍孔底部穿刺入腹,滴水實(shí)驗(yàn)后,連接氣腹裝置向腹腔內(nèi)注入CO2,建立人工氣腹,壓力達(dá)12 mmHg左右,在臍上2橫指取一長(zhǎng)約1.5 cm橫切口,鞘卡帶芯穿刺入腹,置入腹腔鏡,直視下左右下腹部5 mm鞘卡帶芯穿刺建立4個(gè)手術(shù)操作孔。陰道放置舉宮器,鏡下全面探查盆腹腔,了解腫瘤侵襲部位。LigaSure電凝離斷雙側(cè)圓韌帶、高位切斷骨盆漏斗韌帶,再沿髂外動(dòng)脈分別向近心端及遠(yuǎn)心端分離,切除盆腔各組淋巴結(jié),套袋。打開闊韌帶前葉及子宮膀胱返折腹膜,下推膀胱,游離輸尿管,鈍性分離子宮膀胱間隙,閉合、離斷雙側(cè)子宮動(dòng)靜脈;向下鈍性分離宮頸和陰道周圍組織,同法閉合、離斷雙側(cè)子宮骶骨韌帶及主韌帶。環(huán)形切開陰道壁。經(jīng)陰道取出子宮,淋巴組織套袋取出,經(jīng)陰道縫合陰道殘端,中央留2 cm小孔,置入陰道引流管。鏡下觀察腹腔有無(wú)活動(dòng)性出血,溫鹽水沖洗腹腔,排出CO2氣體后,關(guān)腹縫合切口。對(duì)照組:采用廣泛性子宮切除術(shù)及盆腔淋巴結(jié)切除術(shù),術(shù)后防止盆腔引流管3~5 d,留置尿管10~16 d。
①圍手術(shù)期指標(biāo):觀察并記錄2組患者手術(shù)時(shí)間、術(shù)中出血量、淋巴結(jié)清掃數(shù)目、術(shù)后留置尿管時(shí)間、排氣時(shí)間;②觀察并記錄2組患者左、右側(cè)宮旁組織切除長(zhǎng)度,陰道切除長(zhǎng)度;③采用VAS量表對(duì)術(shù)后24 h、術(shù)后1個(gè)月、3個(gè)月的痛覺感受進(jìn)行判定,分值范圍0~10分,分值越低說(shuō)明痛覺感受越輕;④并發(fā)癥:隨訪3個(gè)月期間,觀察并記錄出現(xiàn)的并發(fā)癥。
觀察組患者手術(shù)時(shí)間長(zhǎng)于對(duì)照組患者,但術(shù)中出血量少于對(duì)照組(P<0.05),排氣時(shí)間也短于對(duì)照組(P<0.05);2組淋巴結(jié)清掃數(shù)目、術(shù)后留置尿管時(shí)間相比,無(wú)統(tǒng)計(jì)學(xué)差異(P>0.05);2組各切除范圍相比,無(wú)統(tǒng)計(jì)學(xué)差異(P>0.05)。見表1。
表1 2組圍手術(shù)期指標(biāo)及切除范圍對(duì)比
術(shù)后24 h內(nèi),2組VAS評(píng)分相比,無(wú)統(tǒng)計(jì)學(xué)差異(P>0.05)。術(shù)后1個(gè)月、3個(gè)月,觀察組VAS評(píng)分均低于對(duì)照組(P<0.05),見表2。
表2 2組疼痛感對(duì)比分)
隨訪3個(gè)月,觀察組發(fā)生淋巴囊腫3例、尿潴留5例,總并發(fā)癥發(fā)生率26.7%;對(duì)照組發(fā)生淋巴囊腫7例、臟器損傷1例、尿潴留6例、切口感染2例,總并發(fā)癥發(fā)生率53.3%。觀察組并發(fā)癥發(fā)生率更低 (χ2=1.323,P<0.05)。
手術(shù)仍是婦科惡性腫瘤的首選方法,但傳統(tǒng)開腹手術(shù)創(chuàng)傷大、切口大、患者需要較長(zhǎng)時(shí)間恢復(fù)。故近年來(lái)臨床手術(shù)逐漸向以腹腔鏡為代表的微創(chuàng)手術(shù)過(guò)渡。隨著腹腔鏡相關(guān)設(shè)備及技術(shù)地不斷提高,國(guó)內(nèi)腹腔鏡下根治子宮切除術(shù)及盆腔淋巴結(jié)切除術(shù)已經(jīng)多見臨床報(bào)道,并且陸續(xù)有文獻(xiàn)對(duì)腹腔鏡手術(shù)治療早期子宮惡性腫瘤的有效性及安全性進(jìn)行了肯定[4]。
腹腔鏡治療宮頸癌具有如下優(yōu)勢(shì):①腹腔鏡靈活性高,可通過(guò)調(diào)整鏡頭視角,清晰地顯示一些開腹手術(shù)較難觀察到的隱蔽區(qū)域;②腹腔鏡自帶照明系統(tǒng),可為手術(shù)視野提供適宜亮度,在處理膀胱宮頸韌帶和陰道旁間隙組織時(shí),操作具有更高的準(zhǔn)確性;③腹腔鏡對(duì)細(xì)微結(jié)構(gòu)具有放大作用,對(duì)手術(shù)視野中的血管及盆神經(jīng)的分辨更加清楚,能夠仔細(xì)全面地檢出盆、腹腔臟器及腫瘤轉(zhuǎn)移情況;④手術(shù)創(chuàng)傷小,對(duì)內(nèi)臟器官干擾小[5-6]。然而腹腔鏡手術(shù)也存在著局限性:①腹腔鏡手術(shù)難度較大,需要術(shù)者對(duì)于宮頸的解剖十分熟悉且具備嫻熟的操作技術(shù);②腹腔鏡手術(shù)操作時(shí)間普遍較長(zhǎng),需要延長(zhǎng)麻醉時(shí)間,增加了麻醉蘇醒期并發(fā)癥發(fā)生率[7]。
傳統(tǒng)開腹手術(shù)與腹腔鏡手術(shù)在淋巴結(jié)清掃數(shù)目方面可達(dá)到相同效果,故本研究中2組淋巴結(jié)清掃數(shù)目相比,無(wú)統(tǒng)計(jì)學(xué)差異(P>0.05)。由于腹腔鏡手術(shù)操作的準(zhǔn)確性,對(duì)胃腸等消化器官干擾較小,故術(shù)后腸胃蠕動(dòng)恢復(fù)較快,觀察組排氣時(shí)間短于對(duì)照組(P<0.05)。2組術(shù)后留置尿管時(shí)間無(wú)統(tǒng)計(jì)學(xué)差異,說(shuō)明2種手術(shù)方式對(duì)膀胱功能影響均較小。開展腹腔鏡與經(jīng)宮頸癌根治術(shù),手術(shù)切除范圍仍然嚴(yán)格按照開腹手術(shù)標(biāo)準(zhǔn)進(jìn)行,故2種手術(shù)方式在各手術(shù)切除范圍上沒(méi)有明顯差別(P>0.05)。術(shù)后24 h內(nèi),2組VAS評(píng)分相比,無(wú)統(tǒng)計(jì)學(xué)差異(P>0.05),但術(shù)后1個(gè)月、3個(gè)月,觀察組VAS評(píng)分均低于對(duì)照組(P<0.05)。因?yàn)楦骨荤R手術(shù)所用儀器設(shè)備較為先進(jìn),如采用高頻超聲刀分離宮頸旁軟組織,熱損傷小,傷口愈合快。即使有較大出血也能及時(shí)采用雙極電凝進(jìn)行止血,術(shù)中出血量少,再加上手術(shù)切口較小,故術(shù)后患者恢復(fù)較快,痛覺消失也較快。進(jìn)一步研究發(fā)現(xiàn),隨訪3個(gè)月期間,觀察組并發(fā)癥發(fā)生較少,說(shuō)明腹腔鏡手術(shù)具有更高的安全性。淋巴囊腫是腹腔鏡術(shù)后常見的并發(fā)癥,容易壓迫膀胱,引起患者尿頻甚至繼發(fā)性感染。臨床一般采用微波理療,超聲穿刺引流等方式進(jìn)行治療,也可以采用大黃、芒硝等天然中藥進(jìn)行輔助治療[8]。尿潴留多由支配膀胱運(yùn)動(dòng)功能的神經(jīng)損傷引起,術(shù)后患者可通過(guò)合理鍛煉膀胱功能,盡早應(yīng)用提高膀胱順應(yīng)性的藥物來(lái)降低尿潴留的發(fā)生率。
綜上所述,腹腔鏡下宮頸癌根治術(shù)治療宮頸癌具有較好的效果,手術(shù)創(chuàng)傷小,對(duì)內(nèi)臟器官干擾小,術(shù)后疼痛感輕,并發(fā)癥少,值得臨床推廣使用。
[1] Shou H,Chen Y,Chen Z,et al.Laparoscopic ovarian transposition in young women with cervical squamous cell carcinoma treated by primary pelvic irradiation〔J〕.Eur J Gynaecol Oncol,2015,36(1):25-29.
[2] 權(quán)麗麗,曲麗霞,張志萍.腹腔鏡下宮頸癌根治術(shù)與開腹手術(shù)治療早期宮頸癌的療效對(duì)比分析〔J〕.河北醫(yī)藥,2014,36(19): 2939-2941.
[3] Gallotta V,Ferrandina G,Chiantera V,et al.Laparoscopic r-adical hysterectomy after concomitant chemoradiation in locally advanced cervical cancer:a prospective phase Ⅱ Study〔J〕.J Minim Invasive Gynecol,2015,22(5):877-883.
[4] 于江華,王 峰,付秀紅.腹腔鏡下與開腹宮頸癌根治術(shù)的臨床比較〔J〕.中國(guó)婦產(chǎn)科臨床雜志,2015,16(1): 61-62.
[5] 張百蕾,趙玲軍.腹腔鏡與開腹宮頸癌根治術(shù)的臨床對(duì)比分析〔J〕.現(xiàn)代實(shí)用醫(yī)學(xué),2014,26(3): 272-273.
[6] Kim JY,Lee YH,Chong GO,et al.Comparative study betwe-en total laparoscopic and total robotic radical hysterectomy for cervical carcinoma:clinical study〔J〕.Anticancer Res,2015,35(9):5015-5021.
[7] 劉 梅,唐玉云,唐惠英.宮頸癌腹腔鏡根治術(shù)與開腹手術(shù)的臨床療效分析〔J〕.海南醫(yī)學(xué),2013,24(14): 2077-2079.
[8] Imboden S,Papadia A,Nauwerk M,et al.A comparison of radiocolloid and indocyanine green fluorescence imaging,sentinel lymph node mapping in patients with cervical cancer undergoing laparoscopic surgery〔J〕.Ann Surg Oncol,2015,22(13):4198-4203.
ComparisonofLaparoscopicandOpenSurgeryintheTreatmentofCervicalCancer
HUANGWei,GAOLi,ZHANGYongli.
MaternityandChildHealthCareHospitalofBaoji,Baoji,721000
ObjectiveTo compare the laparoscopic and open surgery in the treatment of cervical cancer.Methods60 patients with cervical cancer were selected,they were divided into 2 groups randomly.The observation group (30 cases) was given radical hysterectomy under laparoscopic.The control group (30 cases) was given open surgery.The efficacy and safety of laparoscopic and open surgery in the treatment of cervical cancer was evaluated by perioperative indexes,resection range,VAS scores after 24 h,1 month and 3 months operation.ResultsThe surgical time of the observation group was longer than that of the control group(P<0.05).But the bleeding volume of the observation group was less than that of the control group(P<0.05).The exhausting time of the observation group was shorter than that of the control group(P<0.05).There were no statistical significance in lymph node dissection number and postoperative indwelling catheter time between the 2 groups.There were no statistical significance on resection range between the 2 groups.24 h after operation,there were no statistical significance in VAS scores between the 2 groups(P>0.05).1 month and 3 months after operation,the VAS scores of the observation group was lower than that of the control group(P<0.05).During 3 months follow-up,the complication rate of the observation group was 26.7%,the complication rate of the control group was 53.3%.The complication rate was lower in the observation group(P<0.05).ConclusionRadical hysterectomy under laparoscopic had a good therapeutic effect on cervical cancer.It has slight operative trauma,small interference on organs,less pain and complications.It is worthy of clinical application.
Open surgery;Laparoscopic surgery;Radical hysterectomy;Cervical cancer;Complication
(ThePracticalJournalofCancer,2017,32:2061~2063)
721000 陜西省寶雞市婦幼保健院
10.3969/j.issn.1001-5930.2017.12.045
R737.33
A
1001-5930(2017)12-2061-03
2016-10-07
2017-04-20)
(編輯:甘艷)